Many interesting studies in the field of prostate cancer (PC) were presented at ESMO 2024. In my opinion three studies deserve to be highlighted: one in the localized setting, one in the metastatic hormone-sensitive setting (mHSPC) and one in the metastatic castration resistant setting (mCRPC).
There were many new developments, including practice-changing clinical trials, presented at this year’s European Society of Medical Oncology (ESMO) Congress in Barcelona. From the vast number of abstracts available in the rapidly evolving field of thoracic oncology, we have selected one abstract that was of particular interest to us: Low-dose versus standard dose pembrolizumab for treatment of advanced-stage non-small cell lung cancer (NSCLC) – Results of the pre-planned interim analysis of the clinical trial NVALT-30
Neoadjuvant therapies have the potential to increase R0 resectability and thereby improving surgical outcomes. Two recent phase II trials, PANDAS/PRODIGE 44 (1) and NICHE-2 (2), investigated neoadjuvant treatment approaches for borderline resectable pancreatic cancer and locally advanced mismatch-repair deficient (dMMR) colon cancer, respectively, with notable implications for clinical practice.
Since 2009, trastuzumab combined with chemotherapy has been the standard of care for HER2-positive metastatic gastric (mGC) and gastroesophageal junction cancer (GEJ), based on findings from the phase 3 ToGA trial (1). However, despite this initial success, the following decade brought a series of negative phase 3 trials, leaving first-line treatment options for HER2-positive gastric and gastroesophageal cancers without significant advancements (2–5).
At ESMO 2024 in Barcelona, various studies regarding the management of non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC) and locally advanced / metastatic (la/m) bladder cancer were presented. This article aims to give a short overview of one outstanding study of each group.
In this article we review 2 studies on CD19 CAR-T cells, which were presented at the annual meeting of the European Hematology Association (EHA) 2024 in Madrid, Spain. The first study investigates the efficacy and safety of CD19 CAR-T cell therapies in ≥75 years old patients. The second trial explores if CD19 CAR-T cells expressing interleukin-10 (IL-10) are more resilient to exhaustion and ultimately show a better response rate in DLBCL or B-ALL.
Dr. med. Thomas von Briel Klinik für Hämatologie und Onkologie Hirslanden Zürich
Trotz der grossen Fortschritte in der Bestrahlungsmedizin kommt es bei einigen Patienten zu gravierenden Entzündungsreaktionen im bestrahlten Hautareal. Offenbar ist die Zusammensetzung des Hautmikrobioms als Risikofaktor von Bedeutung, wie ein deutsches Forscherteam feststellte.
Die europäische Marktzulassung für Ropeginterferon alfa-2b vor fünf Jahren war Anlass, die therapeutischen Optionen für Patienten mit Polycythaemia vera Revue passieren zu lassen. Experten erläuterten an einer Pressekonferenz, wie diese Erweiterung des therapeutischen Arsenals die Chancen der betroffenen Patienten längerfristig verbessert hat.
Kann künstliche Intelligenz (KI) die Dermatologie und speziell das Hautkrebs-Screening verbessern? Am diesjährigen Jahreskongress der Schweizerischen Gesellschaft für Dermatologie und Venerologie zeigten Prof. Dr. Alexander Navarini und Dr. Elisabeth Gössinger vom Universitätsspital Basel, was heute schon möglich ist – und was morgen zu erwarten sein könnte.